CN114286819A - 一种cxcr2拮抗剂的晶型及其应用 - Google Patents

一种cxcr2拮抗剂的晶型及其应用 Download PDF

Info

Publication number
CN114286819A
CN114286819A CN202080050661.9A CN202080050661A CN114286819A CN 114286819 A CN114286819 A CN 114286819A CN 202080050661 A CN202080050661 A CN 202080050661A CN 114286819 A CN114286819 A CN 114286819A
Authority
CN
China
Prior art keywords
degrees
compound
angles
crystalline form
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080050661.9A
Other languages
English (en)
Other versions
CN114286819B (zh
Inventor
高峰
陈远
张鹏
罗云富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Jiake Biotechnology Co ltd
Original Assignee
Shenzhen Jiake Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Jiake Biotechnology Co ltd filed Critical Shenzhen Jiake Biotechnology Co ltd
Publication of CN114286819A publication Critical patent/CN114286819A/zh
Application granted granted Critical
Publication of CN114286819B publication Critical patent/CN114286819B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种CXCR2拮抗剂的晶型，及其在制备治疗CXCR2相关疾病的药物的应用。
Figure DDA0003465546080000011

Description

PCT国内申请，说明书已公开。

Claims (47)

  1. PCT国内申请，权利要求书已公开。
CN202080050661.9A 2019-07-11 2020-07-10 一种cxcr2拮抗剂的晶型及其应用 Active CN114286819B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910626168 2019-07-11
CN2019106261686 2019-07-11
PCT/CN2020/101352 WO2021004531A1 (zh) 2019-07-11 2020-07-10 一种cxcr2拮抗剂的晶型及其应用

Publications (2)

Publication Number Publication Date
CN114286819A true CN114286819A (zh) 2022-04-05
CN114286819B CN114286819B (zh) 2024-03-05

Family

ID=74114365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080050661.9A Active CN114286819B (zh) 2019-07-11 2020-07-10 一种cxcr2拮抗剂的晶型及其应用

Country Status (5)

Country Link
US (1) US20220340549A1 (zh)
EP (1) EP3998256A4 (zh)
JP (1) JP2022539853A (zh)
CN (1) CN114286819B (zh)
WO (1) WO2021004531A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1424910A (zh) * 2000-03-16 2003-06-18 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
CN101472477A (zh) * 2006-04-21 2009-07-01 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
WO2019137484A1 (zh) * 2018-01-11 2019-07-18 南京明德新药研发股份有限公司 Cxcr2拮抗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR041834A1 (es) * 2002-10-29 2005-06-01 Smithkline Beecham Corp Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CN101495113A (zh) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
CR20160557A (es) * 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
BR112017002060A2 (pt) * 2014-07-31 2017-12-26 Glaxosmithkline Ip Dev Ltd novo uso
AU2017231832B2 (en) * 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1424910A (zh) * 2000-03-16 2003-06-18 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
CN101472477A (zh) * 2006-04-21 2009-07-01 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
WO2019137484A1 (zh) * 2018-01-11 2019-07-18 南京明德新药研发股份有限公司 Cxcr2拮抗剂

Also Published As

Publication number Publication date
WO2021004531A1 (zh) 2021-01-14
JP2022539853A (ja) 2022-09-13
CN114286819B (zh) 2024-03-05
EP3998256A1 (en) 2022-05-18
EP3998256A4 (en) 2023-07-19
US20220340549A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
ES2642737T3 (es) Sal de hemisulfato de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato
EA023650B1 (ru) 1-ПИРАЗОЛИЛ-3-(4-((2-АНИЛИНОПИРИМИДИН-4-ИЛ)ОКСИ)НАФТАЛИН-1-ИЛ)МОЧЕВИНЫ КАК ИНГИБИТОРЫ p38 MAP-КИНАЗЫ
CN105372376B (zh) 一种帕瑞昔布钠遗传毒性杂质的检测方法及其应用
WO2010031251A1 (zh) 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
RU2766088C1 (ru) Кристаллическая форма соединения, представляющего собой пролекарство ланостерина, и ее применение в изготовлении лекарственного препарата для лечения катаракты
EA029218B1 (ru) ПРОИЗВОДНЫЕ 2-((4-АМИНО-3-(3-ФТОР-5-ГИДРОКСИФЕНИЛ)-1H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ)МЕТИЛ)-3-(2-(ТРИФТОРМЕТИЛ)БЕНЗИЛ)ХИНАЗОЛИН-4(3H)-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОИНОЗИТИД-3-КИНАЗЫ
US20230285381A1 (en) Novel dizocilpine derivatives as peripheral nmda receptor antagonists
US20180215699A1 (en) Novel adamantane and memantine derivatives as peripheral nmda receptor antagonists
CN114286819A (zh) 一种cxcr2拮抗剂的晶型及其应用
JP4566128B2 (ja) イリノテカン塩酸塩の結晶多形の製造方法
WO2008049317A1 (en) Biphenyl acetate, preparation and uses thereof
CN116559458A (zh) 基于protac蛋白靶向降解技术的活性天然产物靶点鉴定方法及protac化合物
CN107337683B (zh) 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用
CN111918859A (zh) 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
CN104650003A (zh) 一种沃替西汀化合物
WO2024022435A1 (zh) 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
CN107445872B (zh) 一种具有潜在脑靶向性的化合物及其制备方法与应用
CN107663198A (zh) 奥美沙坦酯及其制备方法和用途
CN109422741A (zh) 化合物的盐及其晶型
WO2024002127A1 (zh) 紫杉醇类抗肿瘤化合物
WO2023011512A1 (zh) 苦丁皂苷a化合物的晶型、其药物组合物和用途
EP3328826B1 (en) Novel adamantane and memantine derivatives as peripheral nmda receptor antagonists
CN117285458A (zh) 一种无定型雷芬那辛及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant